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supAR correlates with mortality 
and clinical severity in patients with 
necrotizing soft-tissue infections: 
results from a prospective, 
observational cohort study
peter polzik1, olav Grøndal1, Juliette tavenier2, Martin B. Madsen3, ove Andersen2,4, 
Morten Hedetoft5 & ole Hyldegaard  1
Necrotizing soft tissue infections (NSTI) have a 90-day mortality rate of 18–22%. Tools are needed for 
estimating the prognosis and severity of NstI upon admission. We evaluated soluble urokinase-type 
plasminogen activator receptor (supAR) levels at admission as a prognostic marker of NstI severity and 
mortality. In a prospective, observational cohort study, suPAR was measured in 200 NSTI patients. We 
compared admission supAR levels in survivors and non-survivors, patients with septic shock and non-
shock, amputation and non-amputation, correlations with Simplified Acute Physiology Score II (SAPS 
II) and the sequential organ Failure Assessment (soFA) score. Admission supAR levels were higher in 
septic shock vs. non-septic shock patients (9.2 vs. 5.8 ng/mL, p-value < 0.001) and non-survivors vs. 
survivors (11 vs. 6.1 ng/mL, p-value < 0.001) and correlated with SAPS II (r = 0.52, p < 0.001) and SOFA 
score (r = 0.64, p < 0.001). Elevated suPAR upon admission was associated with 90-day mortality (log-
rank test p < 0.001), however not after adjustment for age, sex, and SOFA score. The AUC for suPAR 
and 90-day mortality was 0.77. We found that suPAR is a promising candidate for prognosis and severity 
in patients with NstI.
Necrotizing soft-tissue infections (NSTIs) are characterized by rapidly progressing soft tissue inflammation and 
necrosis, and can cause septic shock, multiple organ failure and death. Patients can become mortally infected in 
hours. Mortality is 18–23%, and patients with NSTI can require amputation and prolonged rehabilitation1. NSTIs 
are rare, with an annual incidence of 1.69 to 4 per 100,000 per year2,3, but awareness is critical due to their high 
mortality and complication rates.
We currently lack the proper tools to rapidly evaluate the severity and prognosis of NSTI. Furthermore, the 
current consensus is that time to initial surgery is critical and that it should be as soon as possible4. A tool for 
quickly assessing the risk of mortality for a suspected NSTI patient could minimize the delay to primary surgery.
We examined the role of soluble urokinase-type plasminogen activator receptor (suPAR) in patients with 
NSTI. SuPAR is the soluble form of urokinase plasminogen activator receptor (uPAR) after it is cleaved from the 
cell membrane, and reflects the activity of the immune system5. Elevated suPAR levels are associated with the risk 
of currently having or developing acute and chronic conditions including cancer, diabetes mellitus, cardiovascu-
lar disease, and acute exacerbations of chronic obstructive lung disease, severe sepsis and septic shock, multiple 
organ failure as well as predicting mortality during these diseases6–13. High suPAR is also associated with mortal-
ity in patients with bacteremia, bacterial meningitis, systemic inflammatory response syndrome and sepsis14–19.
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We aimed to evaluate the use of admission suPAR levels as a possible tool to assess NSTI severity and 
prognosis.
We hypothesized that suPAR levels were elevated in survivors vs. non-survivors, in patients with septic shock 
vs. non-septic shock and in patients who were amputated vs. not amputated. Furthermore, we theorized that in 
patients with NSTI stratified into no sepsis, sepsis and septic shock as defined by the new Sepsis-3 standardized 
criteria20, plasma suPAR correlates with NSTI patients’ clinical condition as assessed by the Simplified Acute 
Physiology Score II (SAPS II) and by the Sequential Organ Failure Assessment (SOFA) score.
Methods
study design. This study was a prospective, observational cohort study of patients with NSTI admitted to 
Copenhagen University Hospital (CUH), Rigshospitalet. The study was a sub-study of the INFECT project (clin-
icaltrials.gov; NCT01790698). All patients with presumed NSTI were screened and enrolled after diagnosis was 
confirmed by surgery. Patients used for this study were included between February 2013 and February 2016.
Patient inclusion criteria were. 
 1. NSTI based on surgical findings (necrotic or deliquescent soft tissue with widespread undermining of the 
surrounding tissue)
 2. Age ≥18 years
 3. Operated for NSTI at Rigshospitalet.
Patient exclusion criteria were. 
 1. Diagnosed as non-NSTI peroperatively.
An arterial or venous blood sample from each patient was collected into ethylenediaminetetraacetic acid 
(EDTA) sample tubes four times: once upon admission to CUH (baseline) and each of the following three days, 
between 08:00 and 12:00. The anticoagulated blood was put on ice until centrifugation (within 40 minutes of col-
lection, at 3500 rpm for ten minutes). The supernatant (plasma) was stored in 1 mL vials at −80 °C until analysis.
patient management. All patients with NSTI were treated using a standardized protocol consisting of 
frequent surgical evaluation and debridement as necessary, intensive care therapy, immunoglobulin therapy, 
broad-spectrum antibiotics in the form of meropenem, clindamycin and ciprofloxacin and adjuvant hyperbaric 
oxygen therapy.
Data collection. Clinical data from the first seven days in the ICU was entered into an electronic case report 
form. Vital status and time of death, if relevant, were obtained from the Danish Civil Registry.
supAR levels. Blood samples were analyzed at the Clinical Research Center, Copenhagen University 
Hospital, Hvidovre, Denmark. The analysts conducting the suPAR analysis were blinded to patient type and 
outcome. Plasma levels of suPAR were measured using the enzyme-linked immunosorbent assay suPARnostic® 
according to the manufacturer’s instructions (ViroGates A/S, Birkerød, Denmark). The standard curve range for 
the assay was 1.0–17.8 ng/mL, samples above the standard range were diluted appropriately and re-measured. All 
samples from one patient were measured on the same plate, and all the samples were measured in duplicates. The 
intra-assay variance was 3.0%.
outcomes. The primary outcome was the association between plasma suPAR levels measured upon admis-
sion in NSTI patients with and without septic shock, and NSTI day-90 mortality, SAPS II and SOFA scores. The 
stratification into septic shock and non-shock was relevant due to the expected higher mortality rate in septic 
shock patients.
In secondary analyses we compared suPAR levels at admission and during the following three days in the 
ICU between non-shock vs. shock patients, survivors vs. non-survivors and amputations vs. no amputations. 
Additionally, we calculated differences in SOFA and SAPS II levels between survivors and non-survivors, and 
patients with septic shock and non-shock. Patients were followed from admission to either the end of follow up 
(January 2017) or death, whichever came first.
sample size. To the best of our knowledge, suPAR levels during NSTI have never previously been exam-
ined. The sample size calculation was based on a previous study concerning the correlation between suPAR and 
sepsis15. Significant correlations between suPAR, sepsis and mortality were also found in a different study of 132 
patients16. We therefore wanted to include at least 150 patients with NSTI during this study21.
statistics. Data are reported as means with 95% confidence intervals (CI) in parentheses. All following test 
assumptions were met. Continuous data were compared using Wilcoxon rank-sum tests. Correlations were 
assessed using Spearman’s rank test. Categorical data are reported as absolute numbers, with the proportion in 
parentheses, and comparisons done using the Chi-squared test.
Receiver operating characteristic (ROC) curve analysis and areas under the curve (AUC) were applied 
to determine suPAR’s accuracy as a marker of severity and mortality in patients with NSTI. We constructed 
Kaplan-Meier curves with log-rank tests for survival data. Cox multiple regression analysis was used to assess 
mortality hazard ratios. A two-tailed p-value below 0.05 was considered statistically significant.
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Statistical analysis was conducted using R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. R version 3.3.2 and 
RStudio 1.0.136.
ethics. The study was conducted in accordance with the principles of the Declaration of Helsinki. The 
Regional Health Research Ethics Committee (RHREC) and the Danish Data Protection Agency (DDPA) 
approved the study (RHREC document number: H-16021845; DDPA j. no.: RH-2016-199).
Written informed consent was obtained from the patients or their legal surrogates. The study is registered at 
clinicaltrials.gov (NCT03147352).
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were fol-
lowed in the preparation of this manuscript22.
Results
Baseline characteristics. A total of 245 patients were screened for eligibility. Of these, 200 were included 
(Fig. 1).
There were no differences in any of the baseline characteristics of this cohort, as published previously by our 
study group23,24. Our cohort included an additional 40 patients, as compared to the cohort previously published. 
The median age was 61 years (range 53–69) and had a 60/40 male-to-female ratio. See Table 1 for baseline charac-
teristics, (SAPS II and SOFA score values, clinical severity, mortality rates).
19 patients (10%) either died (n = 15) or were discharged (n = 4) prior to Day 4 blood sampling and whose 
Day 4 blood samples were therefore missing in the analyses of biomarker levels and were dealt with by pairwise 
deletion.
Seven patients (3.5%) had missing SAPS II and SOFA score values, exclusively due to missing bilirubin meas-
urements, and were excluded from the multivariate analysis. Follow-up was 99.5% complete, with mortality data 
only missing for one patient: a tourist who left the country permanently 18 days after initial admittance to CUH.
supAR levels and NstI severity and outcome. Admission suPAR levels were higher in non-survivors 
(11 (95% CI, 9.1–13) vs. 6.1 (95% CI, 5.5–6.7) ng/mL, p < 0.001) (Table 1). Admission suPAR levels were also 
higher for septic shock patients (9.2 (8–10.4) vs. 5.8 (5.1–6.6) ng/mL, p < 0.001) (Table 1).
SuPAR levels during the three days following admission in the ICU were significantly different for each 
separate day for survivors vs. non-survivors and shock vs. non-shock groups (Fig. 2). For the amputation vs. 
non-amputation groups, suPAR levels were significantly different for the groups in total (p < 0.001) as well as at 
admission (p = 0.008), and Day 2, 3 and 4 (p-values = 0.02) (Fig. 2).
Moreover, suPAR levels were correlated with both SAPS II (r = 0.52 (95% CI, 0.43–0.63), p-value < 0.001) and 
SOFA score (r = 0.64 (95% CI, 0.53–0.7), p < 0.001).
SuPAR levels and 90-day mortality. Elevated admission suPAR levels were significantly associated with 
90-day mortality in the Kaplan-Meier analysis (log rank test p < 0.001) (Fig. 4). However, after adjustment for 
Figure 1. Patient flow. NSTI, necrotizing soft tissue infection; CUH, Copenhagen University Hospital.
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age, sex, and SOFA score (day 1), admission suPAR levels were not associated with 90-day mortality (hazard ratio 
(HR) 1.07 (95% CI, 0.99–1.15), p = 0.08).
In ROC curve analyses, the AUC for suPAR for predicting 90-day-mortality was 0.77 (0.7–0.85) (Fig. 3). The 
optimal suPAR cutoff value for predicting 90-day mortality (found via the suPAR ROC curve seen in Fig. 3) was 
7.4 ng/mL. This suPAR level could also differentiate patients into groups at lower or higher risk of amputation 
(10% vs. 26%) (Table 1).
We also compared suPAR’s AUC to the accuracy of SAPS II and the SOFA score in predicting mortality. SAPS 
II AUC was 0.87 (0.81–0.92), while SOFA score (day 1) had an AUC of 0.82 (0.74–0.9). Adding all three (SAPS II, 
SOFA score and suPAR) to the model did not improve it compared to SAPS II alone (AUC = 0.87 (0.81–0.92)).
supAR levels and microbiology. Of the 200 patients, we could determine the pathogen responsible for 
NSTI in 178 cases (89%). A single bacterium was responsible in 76 cases (43%). Two or more bacteria were 
responsible for the remaining 102 cases (57%). The largest group of the monomicrobial infections was Group A 
Streptococci (40 cases, 22% of total NSTI pathogens). The rest of the monomicrobial infections were Group B, C 
and G streptococci, staphylococcus aureus, clostridium species or various gram-negative bacteria,
We analyzed suPAR levels for the Group A Streptococci (8.2 (95% CI, 6.7–10)), for the monomicrobials in 
general (7.3 (95% CI, 5.3–9.3)) and for the polymicrobials in general (7.2 (95% CI, 6.3–8.1)). There were no dif-
ferences in suPAR levels between these groups (all p-values above 0.66).
Discussion
Admission suPAR levels were higher in NSTI patients with septic shock, in patients who were amputated and in 
patients who died before day 90. Admission suPAR levels were also correlated with SAPS II and the SOFA score 
day 1. The ROC-AUC for suPAR and mortality was high, though the ROC-AUC for SAPS II and SOFA score day 
1 was higher. SuPAR was not associated with 90-mortality when adjusted for age, sex, and SOFA score day 1. Our 
results show that admission suPAR can indeed approximate NSTI severity and mortality.
Age and chronic diseases have been shown to correlate with suPAR levels. However, in many studies, suPAR 
is still associated with mortality after adjustment for age and chronic diseases14–16,25–27. We wanted to determine 
whether suPAR could predict mortality in NSTI patients. Our data, however, showed that suPAR was not inde-
pendently prognostic for NSTI mortality.
SuPAR has been reported as being active in many different areas of host defense: plasminogen activation, 
inflammation, cell adhesion, mobilization, migration and proliferation, as well as chemotaxis5,28–30. The high 
prognostic accuracy of suPAR has been ascribed to its inhibition of neutrophil phagocytosis, thereby possibly 
directly reflecting immune system impairment19,31,32. This could explain its superiority over C-reactive protein 
and procalcitonin, which are only surrogate markers of inflammation.
SuPAR levels were higher in patients who underwent amputation. This further strengthens the potential of 
using suPAR as a “warning bell” for medical doctors and surgeons who encounter patients with possible NSTI. 
Due to the relative rarity of NSTIs, it is critical that physicians who have limited experience with these infections 
can rapidly assess the prognosis of these patients.
N (%) Mortality, N (%) SAPS II (95% CI) SOFA (95% CI)
Died within 90 days
Yes 43 (22) 62 (58–67) 10.9 (9.9–11.9)
No 157 (78) 41 (39–43) 7.2 (6.7–7.7)
Septic shock
Yes 79 (40) 29 (37) 52 (49–56) 10 (9.4–10.7)
No 121 (60) 14 (12) 42 (39–44) 6.7 (6.1–7.2)
N (%) suPAR (ng/mL) 95% CI P-value
<0.001
Yes 43 (22) 11 7.8–14.2
No 157 (78) 6.1 2.9–9.3
Septic shock <0.001
Yes 79 (40) 9.2 7–11.2
No 121 (60) 5.8 3.6–8
No amputation Amputation Total
suPAR ≤ 7.4 ng/mL 118 (90%) 13 (10%) 131
suPAR ≥ 7.4 ng/mL 51 (74%) 18 (26%) 69
Table 1. Differences in admission SAPS II and SOFA score, plasma suPAR levels between survivors and non-
survivors, septic shock and non-septic shock patients and differences in amputation rates in high vs. low suPAR 
(above or below 7.4 ng/mL) NSTI patients. Data are means (95% CI) or numbers (%). SAPS II Simplified Acute 
Physiology Score II. SOFA Sequential Organ Failure Score. suPAR soluble urokinase-type plasminogen activator 
receptor. NSTI necrotizing soft-tissue infections. Pearson’s Chi-squared test with Yates’ continuity correction, 
Χ2 = 7.8, p-value = 0.005. Optimal cutoff for predicting Day-90 mortality of 7.4 ng/mL was found via the suPAR 
ROC curve. Welch’s t-test, p-value < 0.001.
5Scientific RepoRts |          (2019) 9:5098  | https://doi.org/10.1038/s41598-019-41688-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
The correlation of suPAR with SAPS II and the SOFA score agrees with previous research16,25. Our ROC-AUC 
for mortality and suPAR (AUC = 0.78) is the same as in a previous report in patients with systemic inflam-
matory response syndrome (AUC = 0.8)18. While SAPS II was better than suPAR at predicting mortality in 
our NSTI patient cohort, it cannot be used upon admission. SAPS II relies on 17 variables, some of which are 
time-consuming to acquire, expensive and require manual input from medical personnel33. In addition, these 
variables are not always available for all patients. Furthermore, the SAPS II score is only applicable after 24 hours 
of admission, thereby invalidating it for use in admission triage. The SAPS II score has been updated to SAPS 
III, which can be calculated within 1 hour of ICU admission but requires even more resources and variables to 
calculate, many of which may be missing upon admission. SuPAR, on the other hand, requires only analysis of a 
single blood sample, and can easily be done immediately upon admission. SuPAR levels can be available within 
30 minutes of blood sampling, using a quantitative point of care prognostic triage test.
C-reactive protein, procalcitonin and other standard biochemical marker levels have been shown to have poor 
association with mortality in NSTI patients23. SuPAR has been shown to have superior prognostic value in other 
ICU patients compared to standard biomarkers as well as having minimal circadian variations19. Our results of 
Figure 2. Mean suPAR levels between NSTI survivors and non-survivors, shock and non-shock, and 
amputations and non-amputations. ****Signifies p-value < 0.0001, ***signifies p-value < 0.001, **signifies 
p-value < 0.01, *signifies p-value < 0.05. 19 patients (10%) either died (n = 15) or were discharged (n = 4) prior 
to Day 4 blood sampling and whose Day 4 blood samples were therefore missing in the analyses of biomarker 
levels. Number of patients analyzed on each day: 200 at admission, 194 on Day 2, 190 on Day 3 and 181 on Day 
4. NSTI, necrotizing soft tissue infections; SuPAR, soluble urokinase-type plasminogen activator receptor.
Figure 3. Receiver operating characteristic curves and areas under the curve depicting the diagnostic accuracy 
of suPAR, SOFA score, SAPS II, and all three combined for 90-day mortality in NSTI patients. SuPAR ROC-
AUC: 0.77 (95% CI, 0.7–0.85), SAPS II ROC-AUC: 0.86 (95% CI, 0.91–0.92), SOFA score ROC-AUC: 0.82 
(95% CI, 0.74–0.9), SAPS II + suPAR + SOFA score ROC-AUC: 0.87 (95% CI, 0.81–0.92), SuPAR, soluble 
urokinase-type plasminogen activator receptor; SOFA, Sequential Organ Failure Assessments; SAPS II, 
Simplified Acute Physiological Score II; NSTI, necrotizing soft tissue infections.
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suPAR levels above 12 ng/mL being an optimal cut-off point for mortality prognosis are in line with other studies 
reviewed34. Many of the studies we refer to conclude by describing suPAR’s potential as a triage marker, including 
a systematic review of suPAR’s usefulness during infections19.
The strengths of our study include the prospective design and that it is the first to investigate the prognostic 
value of suPAR in NSTI patients. The predefined study and analysis plan is a major strength21.
Another strength is the inclusion of all NSTI patients who were transferred to our tertiary care hospital during 
the study period, minimizing selection bias. Follow-up rates were very high, negating attrition bias. The simple 
and limited inclusion and exclusion criteria increase the chance of the study cohort reflecting the standard NSTI 
patient. These factors strengthen the study’s external validity. Furthermore, blood sampling and clinical data 
acquisition was standardized and conducted using predefined standard operational procedures. The staff respon-
sible for suPAR analysis was blinded regarding study purpose and patient outcome.
Our study has several limitations. As with other observational studies, unknown confounders are difficult to con-
trol for. NSTI patients are a heterogeneous group, and suPAR levels could be influenced by unknown factors in these 
patients. However, there were no differences in any of the baseline characteristics that we had access to. It is also con-
ceivable that any NSTI patients who were not transferred to CUH in time before they became too critically ill to trans-
port escaped inclusion in our study, thus possibly skewing our results through selection bias. In the present report and 
in line with the statistical analysis plan we did not correlate surgical findings with suPAR levels. Although of interest, 
one should bear in mind that surgical findings are based on a predominantly subjective, clinical description of the 
tissue visualized during the procedure and often not subject to a systematic, histological analysis of tissue destruction 
nor use of objectively verifiable measurements. We acknowledge this as a limitation in present report although it does 
not change the overall conclusion when using suPAR as a potential clinical marker in NSTI triage. A final limitation is 
that we only gathered blood samples during the first three days of admission to CUH, meaning we cannot follow the 
long-term suPAR levels after appropriate treatment was initiated. We can however see that suPAR levels stayed remark-
ably steady for the first few days considering the immediate initiation of treatment upon admission to CUH (Fig. 2).
When taken in conjunction with our present study, we believe that suPAR thus shows great potential as a 
routine clinical marker for NSTI triage upon admission. We suggest that the next step in verification could be a 
randomized-controlled trial, where suPAR is used for NSTI triage in one group to quickly identify the most crit-
ically ill NSTI patients and then investigate differences in mortality and other outcomes. We believe that suPAR 
has the potential to improve patient outcomes while at the same time reducing the costs in time and resources 
involved with NSTI treatment.
Conclusion
We found that plasma suPAR levels are associated with septic shock, amputations and death in patients with 
NSTI. SuPAR levels correlate with SAPS II and SOFA score. SuPAR is associated with 90-day mortality, but not 
when adjusted for age, sex, and SOFA score day 1.
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on rea-
sonable request.
Figure 4. Kaplan-Meier curves of 90-day mortality in NSTI patients stratified by plasma suPAR quartiles. 
P-value is for the log-rank test. NSTI, necrotizing soft tissue infections; SuPAR, soluble urokinase-type 
plasminogen activator receptor.
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